Search

Context: Diabetic peripheral neuropathy (DPN) is a common complication occurring in both type 1 and type 2 diabetics. DPN may result in foot ulceration or lower-limb amputation.Objective: This case was undertaken to evaluate the efficacy of ReBuilder® therapy in the treatment of diabetic peripheral neuropathy.Methods: The case report is based on 3 selected patients, 2 males and 1 female. Each patient continued being managed by his/her primary care physician. No changes to allopathic medicine or diet were advised by our team. In addition to the allopathic therapy, we added ReBuilder® therapy, low level light therapy, vibration therapy and supplementation. The treatment period ranged from 17 to 20 weeks.Conclusion: The data presented here show promise for future, larger, controlled studies on the use of ReBuilder® devices for the treatment of diabetic peripheral neuropathy pain. [ABSTRACT FROM AUTHOR]

The human body is an incredibly complex system, and from time immemorial, humans have struggled to work out what the gut and brain have to do with health and whether the 2 are connected. The parallels between the gut’s and the brain’s immune systems are too self-evident to deny. The similarities extend to the actual structures, mechanisms, and even biochemistries of the 2 systems: the gut immune barrier (GIB) and the blood-brain barrier (BBB). Bidirectional signaling between the brain and the gut has been confirmed by numerous studies. In fact, the communication between the gut and the brain is ongoing from birth and plays a significant role in shaping how the brain is wired. The gut’s influence on the brain cannot be overestimated, so much so that it can be called a second brain. Studies have linked gut-microbiota dysbiosis to brain-linked disorders, such as depression, anxiety, multiple sclerosis, and autism. The scientific community is aware now that neurodegenerative diseases may not exclusively have a neurological trigger. Uncontrolled chronic inflammation, disturbances in the gut microbiota, and other gastrointestinally related dysfunctions have been linked to neurodegenerative disorders. A spotlight has been focused on the role of intestinal-barrier function in the pathogenesis not only of gastrointestinal diseases but also of autoimmune, neuroautoimmune, and neurodegenerative ones. Using predictive antibodies opens the possibility of prevention, amelioration, and even reversal of autoimmune disorders, both gastrointestinal and neurodegenerative, through treatment modalities that involve the repair of the GIB and BBB, thus restoring the functionality of their barriers and the stability of their environments. [ABSTRACT FROM AUTHOR]

Background: There is a subgroup of patients with type 2 diabetes (T2D) in whom traditional treatment does not work well. Traditional management of T2D does not address the autoimmune component seen in a subgroup of patients with T2D.Primary Study Objective: We sought to evaluate the effectiveness of using a personalized functional medicine (PFM) approach to managing T2D.Methods/design: Patient files from 2010 to 2015 were culled for patients previously diagnosed with T2D and their deidentified data regarding medications and T2D biomarker test results were compiled. A total of 35 patients were contacted for permission to use their deidentified data for the purposes of this article. Of 35 patients, 11 provided written consent.Setting: All participants had entered a single, private, integrative medicine clinic based in Maryland, USA.Participants: The patient group consisted of 5 women and 6 men; age 50 to 77 years. Each patient was taking an antidiabetic medication and had reached a plateau in recovery, or wanted to reduce their medication intake. Allopathic physicians were retained by patients undergoing PFM treatment.Intervention: After a thorough intake history was completed, necessary specimens were collected for analysis. Once test results were reviewed to identify nutrient deficiencies, intestinal dysbiosis, hormone imbalances, chemical burden and food immune reactivities, a personalized plan was developed for each individual patient. Each patient was retested appropriately during treatment. Treatment lasted from 2 to 10 months based on the patients' goals.Primary Outcome Measures: The effectiveness of the PFM approach was measured by the reduction in medication needed to manage T2D and improvement in T2D biomarkers.Results: At the end of PFM treatment, 6 patients were completely off T2D-related medications, and 5 had their doses reduced by 50%. Diabetes biomarkers improved: glucose decreased by an average of 78.36 mg/dL and hemoglobin A1c (HbA1c) was lowered by an average of 2.71%.Conclusion: In individuals not well-managed using traditional protocols, the PFM approach should be considered as an adjunct therapy. [ABSTRACT FROM AUTHOR]